DE69841261D1 - Genetisch modifizierte, auf tumoren gezielte bakterien mit verminderter virulenz - Google Patents
Genetisch modifizierte, auf tumoren gezielte bakterien mit verminderter virulenzInfo
- Publication number
- DE69841261D1 DE69841261D1 DE69841261T DE69841261T DE69841261D1 DE 69841261 D1 DE69841261 D1 DE 69841261D1 DE 69841261 T DE69841261 T DE 69841261T DE 69841261 T DE69841261 T DE 69841261T DE 69841261 D1 DE69841261 D1 DE 69841261D1
- Authority
- DE
- Germany
- Prior art keywords
- genetically modified
- tumored
- target bacteria
- reduced virulence
- mutant salmonella
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000894006 Bacteria Species 0.000 title 1
- 230000001018 virulence Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 241000607142 Salmonella Species 0.000 abstract 2
- 241000607149 Salmonella sp. Species 0.000 abstract 1
- 101100021843 Shigella flexneri lpxM1 gene Proteins 0.000 abstract 1
- 101100021844 Shigella flexneri lpxM2 gene Proteins 0.000 abstract 1
- 230000009036 growth inhibition Effects 0.000 abstract 1
- 101150060640 lpxM gene Proteins 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/255—Salmonella (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/879—Salmonella
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/926,636 US6080849A (en) | 1997-09-10 | 1997-09-10 | Genetically modified tumor-targeted bacteria with reduced virulence |
US09/149,832 US6447784B1 (en) | 1997-09-10 | 1998-09-08 | Genetically modified tumor-targeted bacteria with reduced virulence |
PCT/US1998/018701 WO1999013053A1 (en) | 1997-09-10 | 1998-09-09 | Genetically modified tumor-targeted bacteria with reduced virulence |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69841261D1 true DE69841261D1 (de) | 2009-12-10 |
Family
ID=25453492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69841261T Expired - Lifetime DE69841261D1 (de) | 1997-09-10 | 1998-09-09 | Genetisch modifizierte, auf tumoren gezielte bakterien mit verminderter virulenz |
Country Status (5)
Country | Link |
---|---|
US (5) | US6080849A (de) |
KR (1) | KR20010015577A (de) |
AT (1) | ATE447005T1 (de) |
DE (1) | DE69841261D1 (de) |
ZA (1) | ZA988289B (de) |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5997881A (en) * | 1995-11-22 | 1999-12-07 | University Of Maryland, Baltimore | Method of making non-pyrogenic lipopolysaccharide or A |
US6207648B1 (en) * | 1997-07-24 | 2001-03-27 | Trustees Of Boston University | Methods of using cytochrome P450 reductase for the enhancement of P450-based anti-cancer gene therapy |
JP2002500001A (ja) * | 1997-09-10 | 2002-01-08 | ヴァイオン ファーマシューティカルズ、インコーポレーテッド | 低下した毒性を有する遺伝子改変腫瘍標的化細菌 |
US6080849A (en) * | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
US6962696B1 (en) | 1999-10-04 | 2005-11-08 | Vion Pharmaceuticals Inc. | Compositions and methods for tumor-targeted delivery of effector molecules |
CN1420783A (zh) * | 1999-10-04 | 2003-05-28 | 维昂药品公司 | 用于将效应分子定向递送至肿瘤的组合物及方法 |
US20020054865A1 (en) * | 2000-09-21 | 2002-05-09 | Minoru Fujimori | Anaerobic bacterium as a drug for cancer gene therapy |
US7396822B2 (en) | 2001-05-24 | 2008-07-08 | Vaxiion Therapeutics, Inc. | Immunogenic minicells and methods of use |
US20030194798A1 (en) | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
EP1281767A3 (de) | 2001-07-31 | 2003-05-28 | Aladar A. Szalay | Lichtausstrahlende Mikroorganismen und Zellen für die Diagnose und Therapie von Tumoren |
US7015027B1 (en) | 2001-11-20 | 2006-03-21 | Mds (Canada) Inc. | Radiation therapy by accumulation of therapeutic radionuclides in tumor-targeting bacteria |
WO2003063593A1 (en) * | 2002-01-28 | 2003-08-07 | Vion Pharmaceuticals, Inc. | Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent |
US20030207833A1 (en) * | 2002-02-25 | 2003-11-06 | Neil Berkley | Pharmaceutical compositions with minicells |
US20030224369A1 (en) * | 2002-02-25 | 2003-12-04 | Surber Mark W. | Reverse screening and target identification with minicells |
US20030224444A1 (en) * | 2002-02-25 | 2003-12-04 | Sabbadini Roger A. | Antibodies to native conformations of membrane proteins |
US20040005700A1 (en) * | 2002-05-28 | 2004-01-08 | Surber Mark W. | Poroplasts |
US20030228261A1 (en) * | 2002-06-05 | 2003-12-11 | Aladar Szalay | Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue |
EP1369491A1 (de) * | 2002-06-05 | 2003-12-10 | Aladar A. Szalay | Lichtemittierende Mikroorganismen und Zellen für die Diagnose und Therapie von Krankheiten assoziiert mit Wunden oder entzündetem Gewebe |
AU2004289953B2 (en) | 2003-06-18 | 2008-09-25 | Genelux Corporation | Modified recombinant vaccina viruses and other microorganisms, uses thereof |
WO2005030122A2 (en) * | 2003-08-13 | 2005-04-07 | Chiron Corporation | Inactivated host cell delivery of polynucleotides encoding immunogens |
US7390646B2 (en) * | 2003-09-17 | 2008-06-24 | The Regents Of The University Of California | Bacterial vectors and methods of use thereof |
US20050112097A1 (en) * | 2003-11-26 | 2005-05-26 | Hinton Golden S. | Method for the treatment of cancer |
US20070298012A1 (en) * | 2003-12-16 | 2007-12-27 | Ivan King | Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules |
WO2006055024A2 (en) * | 2004-04-05 | 2006-05-26 | Vaxiion Therapeutics, Inc. | Minicells as vaccines |
US20050244375A1 (en) * | 2004-04-29 | 2005-11-03 | Leonard Arnold S | Composition and method of cancer treatment |
EP2365090A1 (de) | 2004-05-21 | 2011-09-14 | The Regents of The University of California | Verfahren zur Verbesserung der Herstellung von Isoprenoid-Zusammensetzungen |
US20060003454A1 (en) * | 2004-07-02 | 2006-01-05 | Conjugon, Inc. | Non-dividing donor cells for gene transfer |
CA2586126C (en) | 2004-11-24 | 2016-06-28 | Yasunobu Kano | Novel shuttle vector |
US8734779B2 (en) * | 2005-04-08 | 2014-05-27 | Anaeropharma Science Inc. | 5-fluorouracil-resistant bacteria and method for production thereof |
US20060270040A1 (en) * | 2005-05-26 | 2006-11-30 | Conjugon, Inc. | Compositions and methods for treating tissue |
KR101444090B1 (ko) | 2005-07-05 | 2014-09-26 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 이소프레노이드 변형 효소를 코드화하는 폴리뉴클레오티드및 그것의 사용방법 |
US7935505B2 (en) * | 2006-05-24 | 2011-05-03 | Scarab Genomics, Llc | Plasmid DNA preparations and methods for producing same |
MX284139B (es) | 2006-05-26 | 2011-02-18 | Amyris Biotechnologies Inc | Produccion de isoprenoides. |
TW200819540A (en) | 2006-07-11 | 2008-05-01 | Genelux Corp | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders |
US20080124355A1 (en) | 2006-09-22 | 2008-05-29 | David Gordon Bermudes | Live bacterial vaccines for viral infection prophylaxis or treatment |
BRPI0716954A2 (pt) | 2006-09-26 | 2013-10-29 | Univ California | Produção de isoprenóides e precursores de isoprenóides |
US7998461B2 (en) * | 2007-11-15 | 2011-08-16 | University Of Massachusetts | Salmonella cancer therapeutics and related therapeutic methods |
EP2242516A1 (de) | 2008-01-11 | 2010-10-27 | Genelux Corporation | Verfahren und zusammensetzungen zum nachweis von bakterien und zur behandlung von erkrankungen und störungen |
US8647642B2 (en) * | 2008-09-18 | 2014-02-11 | Aviex Technologies, Llc | Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment |
US8241623B1 (en) | 2009-02-09 | 2012-08-14 | David Bermudes | Protease sensitivity expression system |
WO2010151609A1 (en) * | 2009-06-24 | 2010-12-29 | Photoswitch Biosciences Inc. | Photoswitch-enabled ion channel assay system |
US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
EP2569425B1 (de) | 2010-05-10 | 2016-07-06 | The Regents of The University of California | Endoribonukleasezusammensetzungen und verfahren zu ihrer verwendung |
WO2012008860A2 (en) | 2010-07-16 | 2012-01-19 | Auckland Uniservices Limited | Bacterial nitroreductase enzymes and methods relating thereto |
WO2012112696A1 (en) | 2011-02-15 | 2012-08-23 | Vaxiion Therapeutics, Inc. | Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells |
US8859256B2 (en) | 2011-10-05 | 2014-10-14 | Genelux Corporation | Method for detecting replication or colonization of a biological therapeutic |
EP2791333B1 (de) | 2011-12-16 | 2019-03-06 | The Board of Trustees of the Leland Stanford Junior University | Opsin-polypeptide und verfahren zu ihrer verwendung |
WO2013128288A1 (en) * | 2012-02-27 | 2013-09-06 | Thelial Technologies S.A. | Monomeric bacterial actin adp-ribosyltransferases as cancer chemotherapeutics |
US20130280170A1 (en) | 2012-04-20 | 2013-10-24 | Aladar A. Szalay | Imaging methods for oncolytic virus therapy |
US9127284B2 (en) | 2012-05-04 | 2015-09-08 | The University Of Hong Kong | Modified bacteria and their uses thereof for the treatment of cancer or tumor |
AU2013290424B2 (en) | 2012-07-19 | 2018-01-25 | Redwood Bioscience, Inc. | Antibody specific for CD22 and methods of use thereof |
BR112015003326A2 (pt) | 2012-08-16 | 2017-07-04 | Ipierian Inc | métodos de tratamento de uma tauopatia |
CN110818798A (zh) | 2012-10-25 | 2020-02-21 | 美国比奥维拉迪维股份有限公司 | 抗补体C1s抗体和其用途 |
EP2914291B1 (de) | 2012-11-02 | 2022-02-23 | Bioverativ USA Inc. | Anti-komplement-c1s-antikörper und verwendungen davon |
US9593339B1 (en) | 2013-02-14 | 2017-03-14 | David Gordon Bermudes | Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment |
CA2914768A1 (en) | 2013-06-10 | 2014-12-18 | Ipierian, Inc. | Methods of treating a tauopathy |
US9737592B1 (en) | 2014-02-14 | 2017-08-22 | David Gordon Bermudes | Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment |
EP3581580A1 (de) | 2014-03-28 | 2019-12-18 | The Board of Trustees of the Leland Stanford Junior University | Manipulierte lichtaktivierte anionenkanalproteine und verfahren zur verwendung davon |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
US20180080051A1 (en) | 2015-03-31 | 2018-03-22 | Exeligen Scientific, Inc. | Cas 9 retroviral integrase and cas 9 recombinase systems for targeted incorporation of a dna sequence into a genome of a cell or organism |
CN108348598B (zh) | 2015-04-06 | 2023-09-01 | 比奥贝拉蒂美国公司 | 人源化抗C1s抗体及其使用方法 |
US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
RU2760582C2 (ru) | 2015-09-02 | 2021-11-29 | Иммутеп С.А.С. | Анти-LAG-3 антитела |
EP3452510A4 (de) | 2016-04-04 | 2020-01-15 | Bioverativ USA Inc. | Anti-komplementfaktor-bb-antikörper und verwendungen davon |
SG11201903012RA (en) | 2016-10-12 | 2019-05-30 | Bioverativ Usa Inc | Anti-c1s antibodies and methods of use thereof |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
BR112019022500A2 (pt) | 2017-04-27 | 2020-06-16 | Regents Of The University Of California | Microrganismos e métodos para produzir canabinoides e derivados canabinoides |
US11168326B2 (en) | 2017-07-11 | 2021-11-09 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
WO2019075220A1 (en) | 2017-10-11 | 2019-04-18 | Bioverativ Usa Inc. | METHODS FOR INDUCING COMPLEMENT ACTIVITY |
KR20210032928A (ko) | 2018-03-08 | 2021-03-25 | 뉴 아틀라스 바이오테크놀로지스 엘엘씨 | 트립타민의 생산 방법 |
CA3176812A1 (en) | 2018-07-11 | 2020-01-16 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
WO2020047161A2 (en) | 2018-08-28 | 2020-03-05 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
WO2020176809A1 (en) | 2019-02-27 | 2020-09-03 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
WO2020206033A1 (en) | 2019-04-02 | 2020-10-08 | Kenjockety Biotechnology, Inc. | Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto |
JP2023501539A (ja) | 2019-11-12 | 2023-01-18 | アクティム・セラピューティクス・インコーポレイテッド | 免疫刺激細菌デリバリープラットフォーム、および治療用産物のデリバリーのためのその使用 |
WO2021113736A1 (en) | 2019-12-05 | 2021-06-10 | Massachusetts Institute Of Technology | Single-domain antibody to chloramphenicol |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
AU2021283080A1 (en) | 2020-06-04 | 2022-12-15 | Kenjockety Biotechnology, Inc. | ABCG2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto |
CA3191433A1 (en) | 2020-08-12 | 2022-02-17 | Actym Therapeutics, Inc. | Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms |
WO2023086796A2 (en) | 2021-11-09 | 2023-05-19 | Actym Therapeutics, Inc. | Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment |
WO2023114658A1 (en) | 2021-12-13 | 2023-06-22 | Kenjockety Biotechnology, Inc. | Anti-abcb1 antibodies |
WO2023159220A1 (en) | 2022-02-18 | 2023-08-24 | Kenjockety Biotechnology, Inc. | Anti-cd47 antibodies |
WO2023192869A1 (en) | 2022-03-28 | 2023-10-05 | University Of Massachusetts | Antigen delivering salmonella for use as a tumor homing beacon to refocus preexisting, vaccine generated t cells to combat cancer |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US29043A (en) * | 1860-07-10 | Improvement in cultivators | ||
JPS57142256A (en) | 1981-02-25 | 1982-09-02 | Kao Corp | Sanitary napkin |
US4436727A (en) * | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
ATE159858T1 (de) * | 1983-09-26 | 1997-11-15 | Ehrenfeld Udo | Mittel und erzeugnis für die diagnose und therapie von tumoren sowie zur behandlung von schwächen der zelligen und humoralen immunabwehr |
CA1321962C (en) | 1985-03-20 | 1993-09-07 | Aizo Matsushiro | Dental caries preventive preparations and method for preparing said preparations |
JPH0696538B2 (ja) | 1985-12-19 | 1994-11-30 | 株式会社アドバンス | 抗発癌剤 |
JPH0761950B2 (ja) | 1986-10-17 | 1995-07-05 | 塩野義製薬株式会社 | 抗腫瘍剤 |
DE3735381A1 (de) | 1987-03-31 | 1989-05-03 | Boehringer Mannheim Gmbh | Rekombinante dna zur reprimierbaren und induzierbaren expression von fremdgenen |
GB8730037D0 (en) | 1987-12-23 | 1988-02-03 | Wellcome Found | Vaccines |
JPH01180830A (ja) | 1988-01-11 | 1989-07-18 | Kayaku:Kk | 抗腫瘍剤 |
EP0338679A3 (de) | 1988-03-24 | 1991-03-06 | Genentech, Inc. | Tumor Necrosis Faktor zur Behandlung von Blasenkrebs |
JPH0284172A (ja) | 1988-07-21 | 1990-03-26 | Smithkline Beckman Corp | 異種遺伝子の発現能を有し、組換え型ワクチンとして有用なサルモネラ形質転換体 |
GB8912330D0 (en) | 1989-05-30 | 1989-07-12 | Wellcome Found | Live vaccines |
JPH0376580A (ja) * | 1989-08-17 | 1991-04-02 | Japan Tobacco Inc | 大腸菌発現ベクターとそれを利用した抗ウイルス性タンパク質の製造方法 |
ATE167061T1 (de) | 1989-11-03 | 1998-06-15 | Univ Washington | Kreuzschützende salmonella impfstoffe |
US5830702A (en) * | 1990-10-31 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response |
WO1992011361A1 (en) * | 1990-12-18 | 1992-07-09 | The General Hospital Corporation | Improved vaccines |
US5695983A (en) * | 1990-12-18 | 1997-12-09 | The General Hospital Corporation | Salmonella vaccines |
AU664360B2 (en) | 1991-03-05 | 1995-11-16 | Wellcome Foundation Limited, The | Expression of recombinant proteins in attenuated bacteria |
IL101409A0 (en) | 1992-03-29 | 1992-11-15 | Era Masis Ltd | Method for the early diagnosis of cancer |
IL101410A0 (en) | 1992-03-29 | 1992-11-15 | Era Masis Ltd | Formulation for the treatment of cancer |
JPH06298657A (ja) | 1993-04-15 | 1994-10-25 | Nippon Shoji Kk | 免疫強化剤 |
CA2146242A1 (en) | 1993-08-25 | 1995-03-02 | Kazuo Ichihara | Heart function restorative |
US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
JPH09504518A (ja) | 1993-10-06 | 1997-05-06 | アメリカ合衆国 | 負の選択マーカーおよびサイトカインをコード化する遺伝子を用いる腫瘍細胞の遺伝子転換による腫瘍の治療 |
IT1270123B (it) * | 1994-10-05 | 1997-04-28 | Dompe Spa | Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia |
US6051237A (en) * | 1994-11-08 | 2000-04-18 | The Trustees Of The University Of Pennsylvania | Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector |
US6150170A (en) * | 1998-05-03 | 2000-11-21 | University Of Maryland At Baltimore | Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same |
US5877159A (en) | 1995-05-03 | 1999-03-02 | University Of Maryland At Baltimore | Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same |
US5705151A (en) * | 1995-05-18 | 1998-01-06 | National Jewish Center For Immunology & Respiratory Medicine | Gene therapy for T cell regulation |
US6190657B1 (en) | 1995-06-07 | 2001-02-20 | Yale University | Vectors for the diagnosis and treatment of solid tumors including melanoma |
AU731061B2 (en) | 1995-09-06 | 2001-03-22 | Department Of The Army, U.S. Government | Bacterial delivery system |
US5824538A (en) | 1995-09-06 | 1998-10-20 | The United States Of America As Represented By The Secretary Of The Army | Shigella vector for delivering DNA to a mammalian cell |
GB9521568D0 (en) | 1995-10-20 | 1995-12-20 | Lynxvale Ltd | Delivery of biologically active polypeptides |
WO1997018225A1 (en) | 1995-11-14 | 1997-05-22 | The General Hospital Corporation | Salmonella secreted proteins and uses thereof |
US5997881A (en) * | 1995-11-22 | 1999-12-07 | University Of Maryland, Baltimore | Method of making non-pyrogenic lipopolysaccharide or A |
US6887483B2 (en) * | 1995-12-01 | 2005-05-03 | University Of Iowa Research Foundation | Non-toxic mutants of pathogenic gram-negative bacteria |
WO1997025061A1 (en) * | 1996-01-09 | 1997-07-17 | Bristol-Myers Squibb Company | De-myristolated lipopolysaccharide of gram-negative bacteria |
PT884997E (pt) | 1996-02-16 | 2002-11-29 | Janssen Pharmaceutica Nv | Composicoes contendo um fungicida e um composto sulfurado |
AU721819B2 (en) | 1996-05-10 | 2000-07-13 | Pharmacia & Upjohn Company | Topical administration of antimicrobial agents for the treatment of systemic bacterial diseases |
GB9621091D0 (en) | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
TW373083B (en) | 1996-12-20 | 1999-11-01 | Corning Inc | Reflective coupling array for optical waveguide |
WO1998033923A1 (en) | 1997-01-30 | 1998-08-06 | Imperial College Of Science, Technology & Medicine | MUTANT msbB or htrB GENES |
WO1998044131A1 (en) * | 1997-03-28 | 1998-10-08 | Walter Reed Army Institute Of Research | Antimicrobial mediated bacterial dna delivery |
US6537558B2 (en) * | 1997-03-31 | 2003-03-25 | Megan Health, Inc. | Methods of producing and using virulence attenuated poxR mutant bacteria |
US6080849A (en) * | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
JP2002500001A (ja) * | 1997-09-10 | 2002-01-08 | ヴァイオン ファーマシューティカルズ、インコーポレーテッド | 低下した毒性を有する遺伝子改変腫瘍標的化細菌 |
US6143551A (en) * | 1997-12-29 | 2000-11-07 | Schering Aktiengesellschaft | Delivery of polypeptide-encoding plasmid DNA into the cytosol of macrophages by attenuated listeria suicide bacteria |
US6593592B1 (en) * | 1999-01-29 | 2003-07-15 | Semiconductor Energy Laboratory Co., Ltd. | Semiconductor device having thin film transistors |
US6962696B1 (en) * | 1999-10-04 | 2005-11-08 | Vion Pharmaceuticals Inc. | Compositions and methods for tumor-targeted delivery of effector molecules |
CN1420783A (zh) | 1999-10-04 | 2003-05-28 | 维昂药品公司 | 用于将效应分子定向递送至肿瘤的组合物及方法 |
EP1281767A3 (de) * | 2001-07-31 | 2003-05-28 | Aladar A. Szalay | Lichtausstrahlende Mikroorganismen und Zellen für die Diagnose und Therapie von Tumoren |
US20070298012A1 (en) * | 2003-12-16 | 2007-12-27 | Ivan King | Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules |
-
1997
- 1997-09-10 US US08/926,636 patent/US6080849A/en not_active Expired - Lifetime
-
1998
- 1998-09-08 US US09/149,832 patent/US6447784B1/en not_active Expired - Lifetime
- 1998-09-09 KR KR1020007002535A patent/KR20010015577A/ko not_active Application Discontinuation
- 1998-09-09 DE DE69841261T patent/DE69841261D1/de not_active Expired - Lifetime
- 1998-09-09 AT AT98946891T patent/ATE447005T1/de not_active IP Right Cessation
- 1998-09-10 ZA ZA988289A patent/ZA988289B/xx unknown
-
1999
- 1999-06-22 US US09/337,689 patent/US6475482B1/en not_active Expired - Fee Related
-
2002
- 2002-04-18 US US10/125,328 patent/US6923972B2/en not_active Expired - Fee Related
-
2005
- 2005-04-28 US US11/117,085 patent/US7514089B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6447784B1 (en) | 2002-09-10 |
US7514089B2 (en) | 2009-04-07 |
KR20010015577A (ko) | 2001-02-26 |
US20030170276A1 (en) | 2003-09-11 |
ATE447005T1 (de) | 2009-11-15 |
US6080849A (en) | 2000-06-27 |
US20020026655A1 (en) | 2002-02-28 |
US6923972B2 (en) | 2005-08-02 |
US6475482B1 (en) | 2002-11-05 |
US20070009489A1 (en) | 2007-01-11 |
ZA988289B (en) | 1999-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69841261D1 (de) | Genetisch modifizierte, auf tumoren gezielte bakterien mit verminderter virulenz | |
HK1033956A1 (en) | Genetically modified tumor-targeted bacteria with reduced virulence | |
DE69631423D1 (de) | Chinolone und deren therapeutische verwendung | |
FI964681A0 (fi) | Ihmisperäiset Lactobacillus-kannat, niitä sisältävät valmisteet ja niiden käytöt | |
WO1993008259A3 (en) | Inhibitors of dipeptidyl-aminopeptidase type IV | |
HUP9801826A2 (hu) | HER-2/neu-fehérje intracelluláris doménje, és alkalmazása malignitások megelőzésére és kezelésére | |
DK1005353T3 (da) | Farmaceutisk præparat omfattende Lactobacillus casei rhamnosus | |
FI961621A0 (fi) | Proteiini:farnesyylitranseraasin substituoidut tetra- ja pentapeptidi-inhibiittorit | |
BG107537A (en) | Method for the inhibition of human tnf alpha activity and its application | |
MX9800922A (es) | Quinolonas y su uso terapeutico. | |
BG102708A (en) | 4-aminopyrimidine derivatives, medicamentous preparations containing them, their application and method for their preparation | |
BR9805544A (pt) | Uso de um composto. | |
WO1996035784A3 (de) | Chromatin-regulatorgene | |
PT815087E (pt) | Derivados de fenilo trissubstituidos | |
DE69322166T2 (de) | Prüfung auf ein vielfache resistenz gegen antibiotika verursachendes operon | |
ES2184861T3 (es) | Compuestos peptidicos inhibidores de la liberacion de la metaloproteinasa y del tnf y su utilizacion terapeutica. | |
ES2187648T3 (es) | Metodo para la administracion de farmacos para terapia genica. | |
EA200100700A1 (ru) | Гены и белки и их применение | |
HK1024265A1 (en) | Mutants of streptococcal toxin c and methods of use | |
PT1294874E (pt) | Variantes de cd154 e as suas utilizacoes | |
EA200200704A1 (ru) | Ослабленные микроорганизмы для лечения инфекции | |
NZ515727A (en) | Aminotetralin derivative for the therapy of cardiovascular diseases | |
AU2002249173A1 (en) | Phosphorylated glyoxalase i and its use | |
IT1276454B1 (it) | Metodo per la diagnosi di infezioni helycobacter pylori e relativo corredo diagnostico. | |
DE69901104D1 (de) | Verwendung von mikroorganismen extrakten in kosmetischen oder pharmazeutischen zusammensetzungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |